Step-down steroid-sparing therapy in active thyroid eye disease

Research output: Contribution to journalArticle

Abstract

Intravenous steroid therapy in thyroid eye disease has limitations and is potentially harmful at high doses. A steroid-sparing approach is a reasonable option, but combination therapy must be tested in randomized clinical trials designed to establish the efficacy and the potentially increased risk of adverse effects of combined immunosuppressive treatment.

Original languageEnglish
Pages (from-to)634-635
JournalNature Reviews Endocrinology
Volume14
Issue number11
DOIs
Publication statusPublished - 2018

Fingerprint

Thyroid Gland
Steroids
Eye Diseases
Thyroid Diseases
Immunosuppressive Agents
Randomized Controlled Trials
Therapeutics

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Step-down steroid-sparing therapy in active thyroid eye disease. / Salvi, Mario.

In: Nature Reviews Endocrinology, Vol. 14, No. 11, 2018, p. 634-635.

Research output: Contribution to journalArticle

@article{195eeb0bec1f47419c205d629dc66b00,
title = "Step-down steroid-sparing therapy in active thyroid eye disease",
abstract = "Intravenous steroid therapy in thyroid eye disease has limitations and is potentially harmful at high doses. A steroid-sparing approach is a reasonable option, but combination therapy must be tested in randomized clinical trials designed to establish the efficacy and the potentially increased risk of adverse effects of combined immunosuppressive treatment.",
author = "Mario Salvi",
year = "2018",
doi = "10.1038/s41574-018-0099-9",
language = "English",
volume = "14",
pages = "634--635",
journal = "Nature Reviews Endocrinology",
issn = "1759-5029",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Step-down steroid-sparing therapy in active thyroid eye disease

AU - Salvi, Mario

PY - 2018

Y1 - 2018

N2 - Intravenous steroid therapy in thyroid eye disease has limitations and is potentially harmful at high doses. A steroid-sparing approach is a reasonable option, but combination therapy must be tested in randomized clinical trials designed to establish the efficacy and the potentially increased risk of adverse effects of combined immunosuppressive treatment.

AB - Intravenous steroid therapy in thyroid eye disease has limitations and is potentially harmful at high doses. A steroid-sparing approach is a reasonable option, but combination therapy must be tested in randomized clinical trials designed to establish the efficacy and the potentially increased risk of adverse effects of combined immunosuppressive treatment.

UR - http://www.scopus.com/inward/record.url?scp=85054013765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054013765&partnerID=8YFLogxK

U2 - 10.1038/s41574-018-0099-9

DO - 10.1038/s41574-018-0099-9

M3 - Article

VL - 14

SP - 634

EP - 635

JO - Nature Reviews Endocrinology

JF - Nature Reviews Endocrinology

SN - 1759-5029

IS - 11

ER -